CAMP4 Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
48
- Stock Symbol
-
CAMP
- Share Price
-
$3.80
- (As of Friday Closing)
CAMP4 General Information
Description
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Contact Information
Website
www.camp4tx.comCorporate Office
- One Kendall Square
- Building 1400 West, 3rd Floor
- Cambridge, MA 02139
- United States
Corporate Office
- One Kendall Square
- Building 1400 West, 3rd Floor
- Cambridge, MA 02139
- United States
CAMP4 Timeline
CAMP4 Stock Performance
As of 13-Nov-2026, CAMP4’s stock price is $3.80. Its current market cap is $238M with 62.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.80 | $4.09 | $2.90 - $7.75 | $238M | 62.8M | 251K | -$2.11 |
CAMP4 Financials Summary
As of 30-Sep-2026, CAMP4 has a trailing 12-month revenue of $5.32M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 169,497 | 249,122 | 274,310 | |
| Revenue | 5,320 | 3,498 | 652 | 350 |
| EBITDA | (122,582) | (80,938) | (51,425) | (50,421) |
| Net Income | (121,101) | (80,403) | (51,791) | (49,291) |
| Total Assets | 134,013 | 117,808 | 78,307 | 54,946 |
| Total Debt | 6,450 | 1,974 | 8,487 | 11,693 |
CAMP4 Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CAMP4 Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
CAMP4 Comparisons
Industry
Financing
Details
CAMP4 Competitors (32)
One of CAMP4’s 32 competitors is Seres Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Synlogic | Formerly VC-backed | Winchester, MA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA |
CAMP4 Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CAMP4 Patents
CAMP4 Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026151811-A1 | Compositions and methods for treating urea cycle disorders | Pending | 07-Jan-2025 | ||
| WO-2025255388-A1 | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas | Pending | 05-Jun-2024 | ||
| AU-2023403208-A1 | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas | Pending | 01-Dec-2022 | ||
| EP-4627084-A1 | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas | Pending | 01-Dec-2022 | ||
| US-20250290072-A1 | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas | Pending | 01-Dec-2022 | C12N15/113 |
CAMP4 Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CAMP4 Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CAMP4 ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
CAMP4 FAQs
-
When was CAMP4 founded?
CAMP4 was founded in 2016.
-
Where is CAMP4 headquartered?
CAMP4 is headquartered in Cambridge, MA.
-
What is the size of CAMP4?
CAMP4 has 48 total employees.
-
What industry is CAMP4 in?
CAMP4’s primary industry is Biotechnology.
-
Is CAMP4 a private or public company?
CAMP4 is a Public company.
-
What is CAMP4’s stock symbol?
The ticker symbol for CAMP4 is CAMP.
-
What is the current stock price of CAMP4?
As of 13-Nov-2026 the stock price of CAMP4 is $3.80.
-
What is the current market cap of CAMP4?
The current market capitalization of CAMP4 is $238M.
-
What is CAMP4’s current revenue?
The trailing twelve month revenue for CAMP4 is $5.32M.
-
Who are CAMP4’s competitors?
Seres Therapeutics, Agenus, Synlogic, Intellia Therapeutics, and Editas Medicine are some of the 32 competitors of CAMP4.
-
What is CAMP4’s annual earnings per share (EPS)?
CAMP4’s EPS for 12 months was -$2.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
